Merck Animal Health’s Nobivac NXT Canine Flu H3N2 Receives the USDA’s Approval for Canine Influenza
Shots:
- The USDA has approved to Merck Animal Health’s Nobivac NXT Canine Flu H3N2 vaccine to prevent canine influenza in dogs. Its global availability is anticipated during late summer
- Nobivac NXT Canine Flu H3N2 (low volume of 0.5mL), developed using Nobivac NXT technology, is a nonadjuvanted vaccine intended for healthy dogs (≥8wks. of age) to prevent canine influenza. It makes use of the body’s natural capability of immune system to produce strong responses
- NOBIVAC NXT is a groundbreaking RNA-particle vaccine for companion animals, providing precise immune protection against various viral and bacterial pathogens
Ref: Merck | Image: Merck
Related News:- Merck Animal Health’s Innovax-ND-H5 Vaccine Gains the EC’s Marketing Authorization for Chickens
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
